Quality of life after radio frequency ablation turbinate reduction (RFATR) among patients with rhinitis medicamentosa & withdrawal from decongestant topical spray abuse
Copyright © 2023 Elsevier Inc. All rights reserved..
OBJECTIVE: Radiofrequency ablation (RFA) reliefs nasal obstruction and improves quality of life (QoL) in patients suffering from inferior turbinate hypertrophy (ITH). A substantial benefit was noted among patients suffering from Rhinitis Medicamentosa (RM), enabling ending decongestant spray abuse. Our aim was to establish the benefit from RFA with respect to QoL in patients suffering from ITH, due to the presence of RM.
STUDY DESIGN: Prospective cohort study.
METHODS: Prospective Cohort study, including patients suffering from ITH undergoing RFA between 9.2017 and 9.2019 in Tel Aviv Medical Center. The cohort was divided to RM and non-RM (including allergic, non-allergic) patients. The differences between the groups were compared before and after RFA, and included patients' complaints, clinical findings and QoL questionnaires (SNOT-22 & NOSE). In the RM group, the ability to wean from decongestants was also described.
RESULTS: Our data demonstrated subjective QoL improvement following RFA (88.9 %, N = 90). All RM patients withdrawaled from nasal decongestant spray. NOSE questionnaire demonstrated a significant improvement in QoL after RFA in the RM group (PV = 0.025). SNOT-22 did not demonstrate significant difference in QoL between RM and the reference group (PV = 0.1). Rates of MCID>8.3 were high, without significant difference between the groups (PV = 0.2).
CONCLUSION: RFA demonstrated effectiveness in achieving of withdrawal from decongestant spray in RM patients and may be a possible definitive treatment option for this group. The nasal obstruction component in SNOT-22 questionnaire & NOSE questionnaire showed improved QoL in comparison to controls. High QoL after RFA was established in our entire cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
American journal of otolaryngology - 44(2023), 4 vom: 01. Juli, Seite 103842 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carmel Neiderman, Narin N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Inferior turbinate hypertrophy |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 12.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjoto.2023.103842 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354947001 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354947001 | ||
| 003 | DE-627 | ||
| 005 | 20231226063320.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjoto.2023.103842 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM354947001 | ||
| 035 | |a (NLM)36989755 | ||
| 035 | |a (PII)S0196-0709(23)00056-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carmel Neiderman, Narin N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quality of life after radio frequency ablation turbinate reduction (RFATR) among patients with rhinitis medicamentosa & withdrawal from decongestant topical spray abuse |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 12.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: Radiofrequency ablation (RFA) reliefs nasal obstruction and improves quality of life (QoL) in patients suffering from inferior turbinate hypertrophy (ITH). A substantial benefit was noted among patients suffering from Rhinitis Medicamentosa (RM), enabling ending decongestant spray abuse. Our aim was to establish the benefit from RFA with respect to QoL in patients suffering from ITH, due to the presence of RM | ||
| 520 | |a STUDY DESIGN: Prospective cohort study | ||
| 520 | |a METHODS: Prospective Cohort study, including patients suffering from ITH undergoing RFA between 9.2017 and 9.2019 in Tel Aviv Medical Center. The cohort was divided to RM and non-RM (including allergic, non-allergic) patients. The differences between the groups were compared before and after RFA, and included patients' complaints, clinical findings and QoL questionnaires (SNOT-22 & NOSE). In the RM group, the ability to wean from decongestants was also described | ||
| 520 | |a RESULTS: Our data demonstrated subjective QoL improvement following RFA (88.9 %, N = 90). All RM patients withdrawaled from nasal decongestant spray. NOSE questionnaire demonstrated a significant improvement in QoL after RFA in the RM group (PV = 0.025). SNOT-22 did not demonstrate significant difference in QoL between RM and the reference group (PV = 0.1). Rates of MCID>8.3 were high, without significant difference between the groups (PV = 0.2) | ||
| 520 | |a CONCLUSION: RFA demonstrated effectiveness in achieving of withdrawal from decongestant spray in RM patients and may be a possible definitive treatment option for this group. The nasal obstruction component in SNOT-22 questionnaire & NOSE questionnaire showed improved QoL in comparison to controls. High QoL after RFA was established in our entire cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Inferior turbinate hypertrophy | |
| 650 | 4 | |a NOSE | |
| 650 | 4 | |a Nasal decongestants | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a RFA | |
| 650 | 4 | |a Rhinitis | |
| 650 | 4 | |a Rhinitis medicamentosa | |
| 650 | 4 | |a SNOT-22 | |
| 650 | 4 | |a Withdrawal | |
| 650 | 7 | |a Nasal Decongestants |2 NLM | |
| 700 | 1 | |a Caspi, Inbar |e verfasserin |4 aut | |
| 700 | 1 | |a Eisenberg, Netanela |e verfasserin |4 aut | |
| 700 | 1 | |a Halevy, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Wengier, Anat |e verfasserin |4 aut | |
| 700 | 1 | |a Shpigel, Iris |e verfasserin |4 aut | |
| 700 | 1 | |a Ziv Baran, Tomer |e verfasserin |4 aut | |
| 700 | 1 | |a Ringel, Barak |e verfasserin |4 aut | |
| 700 | 1 | |a Warshavsky, Anton |e verfasserin |4 aut | |
| 700 | 1 | |a Abergel, Avraham |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of otolaryngology |d 1993 |g 44(2023), 4 vom: 01. Juli, Seite 103842 |w (DE-627)NLM000961876 |x 1532-818X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:4 |g day:01 |g month:07 |g pages:103842 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjoto.2023.103842 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 4 |b 01 |c 07 |h 103842 | ||